Study Stopped
This study has been withdrawn because the drug would not meet trial criteria for efficacy
Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme
1 other identifier
interventional
323
2 countries
25
Brief Summary
TransMID treatment or best standard of care for patients with advanced glioblastoma multiforme Glioblastoma multiforme (GBM) is a type of brain tumour. GBM tumours are usually treated with surgery and radiotherapy. Unfortunately, this type of brain tumour may continue to grow or come back (recur) despite treatment. This trial will compare a new drug called TransMID with the best standard treatment that is currently available. TransMID is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. Cancer cells need iron in order to continue to grow. They need more iron than normal cells. Transferrin helps cells to take up available iron. So the cancer cells are attached to the transferrin in TransMID, and the diphtheria poison kills them. The aim of this treatment is to kill the cancer cells while not affecting the normal brain cells. This treatment for brain tumours may have fewer side effects than other treatments because it targets cancer cells. The best standard treatment will involve giving chemotherapy. You may have chemotherapy as part of the treatment when you are diagnosed. Or it may be kept in reserve to treat your brain tumour if it comes back or continues to grow. Your cancer specialist (consultant) will decide which chemotherapy drugs you should have.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started May 2004
Typical duration for phase_3
25 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2004
CompletedFirst Submitted
Initial submission to the registry
May 24, 2004
CompletedFirst Posted
Study publicly available on registry
May 26, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2007
CompletedJanuary 7, 2009
January 1, 2008
1.8 years
May 24, 2004
January 6, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival time i.e. to to death
Secondary Outcomes (8)
12 month survival rate
Tumor Response
Duration of Response
Time to Progression
6 and 12 month progression rates
- +3 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- \) Male or female at least 18 years of age 2) Histological results confirming GBM are available 3) Progressive GBM (≥ 25% increase in contrast enhanced tumor CSA compared to the nadir or smallest previous measured CSA) and/or recurrent GBM after conventional treatment, including surgery (biopsy or debulking surgery) and/or radiation therapy and/or chemotherapy 4) Pre-study MRIs used to determine current progression and/or recurrence of GBM are available to the Investigator and for independent confirmation of progression and/or recurrence 5) Patient is not considered a candidate for resection 6) If female of child-bearing potential, a reliable method of contraception must be combined with a negative pregnancy test before entering the study (female patients must be willing to use contraception for 2 months after the last treatment with TransMID™). Male patients must be willing to use a barrier method of contraception for up to 2 months after the last treatment with TransMID™ 7) Able and willing to follow instructions and comply with the protocol 8) Provide written informed consent prior to participation in the study 9) Karnofsky Performance Scale Score 70-100 10) Tumor characteristics: i) must be unifocal; and ii) must be unilateral and supratentorial; and iii) lesion must have a diameter (on contrast-enhanced MRI) ≥1.0 cm and ≤4.0 cm
You may not qualify if:
- \) Anticipated life expectancy of less than 3 months 2 Infratentorial or intraventricular tumors 3) Presence of satellite tumors 4) Chemotherapy within 30 days prior to study entry or nitrosoureas or Mitomycin-C containing therapy within 42 days prior to study entry 5) External Beam irradiation within 60 days prior to study entry or stereotactic (gamma knife) radiosurgery within 90 days prior to study entry 6) Tumor surgery, tumor debulking or other neurosurgery within 5 days prior to study entry 7) Previous administration of TransMID™ 8) Previous enrollment in this study 9) Regional therapy including administration of biodegradable polymer wafers containing carmustine within 90 days prior to study entry or brachytherapy within 12 calendar months prior to study entry 10) Significant liver function impairment - AST or ALT \> 2 times the upper limit of normal, total bilirubin \> upper limit of normal 11) Hepatitis B surface antigen positive or positive Anti-Hepatitis C antibodies, or previous history of infectious Hepatitis (except previous Hepatitis A infection) 12) Significant renal impairment (serum creatinine \> 1.7 mg/dL or 150 µmol/L) 13) Coagulopathy (prothrombin time \[PT\] or activated partial thromboplastin time \[APTT\] \>1.5 times control) 14) Thrombocytopenia (platelet count \< 100 x 103/μL or 100 x 109/L) 15) Granulocytopenia (absolute neutrophil count (ANC), \< 1 x 103/μL or 1.0 x 109/L) 16) Severe acute infection 17) Medical condition that is considered an unacceptable anesthetic risk 18) Evidence of a mass effect on CT or MRI with more than a 5 mm midline shift and/or nausea, vomiting, reduced level of consciousness or clinically significant papilledema 19) Nursing or pregnant females. A pregnancy test will be performed on all females who are of child-bearing potential 20) Use of any investigational product and/or participation in another clinical research study within the last 30 days prior to study entry
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xenova Biomedixlead
Study Sites (25)
University of California-San Diego
La Jolla, California, 92037-0698, United States
University of Southern California
Los Angeles, California, 90033, United States
University of Colorado Health Sciences Center
Denver, Colorado, 80010, United States
Yale University
New Haven, Connecticut, 06520, United States
Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
University of Chicago
Chicago, Illinois, 60637, United States
University of Iowa Hospitals in Clinics
Cedar Rapids, Iowa, 52242, United States
University of Kentucky Medical Center
Lexington, Kentucky, 40536, United States
Johns Hopkins Medical Center
Baltimore, Maryland, 21287, United States
NINDS National Institutes of Health
Bethesda, Maryland, United States
Fairview University Medical Center
Minneapolis, Minnesota, 55455, United States
Saint Louis University Hospital
St Louis, Missouri, 63110, United States
Cooper University Hospital
Camden, New Jersey, 08103, United States
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Columbia University Medical Center
New York, New York, 10032, United States
SUNY Upstate Medical University at Syracuse
Syracuse, New York, 13210, United States
New York Medical College
Valhalla, New York, 10595, United States
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Legacy Emanuel Hospital and Technology Center
Portland, Oregon, 97227, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Semmes-Murphey Neurologic Institute
Memphis, Tennessee, 38104, United States
University of Utah
Salt Lake City, Utah, 84132, United States
Medical College of Virginia
Richmond, Virginia, 23298-0631, United States
Neville Knuckey, MD
Nedlands, Western Australia, 6009, Australia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 24, 2004
First Posted
May 26, 2004
Study Start
May 1, 2004
Primary Completion
March 1, 2006
Study Completion
June 1, 2007
Last Updated
January 7, 2009
Record last verified: 2008-01